Stifel Nicolaus Upgrades Inverness Medical Innovations (IMA) to Buy
IMA Hot Sheet
Rating Summary:0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 24 | Down: 13 | New: 29
Stifel Nicolaus upgrades Inverness Medical Innovations (AMEX: IMA) from Hold to Buy with a $58 price target. The firm said, "We like both the strategic and financial impact of the Cholestech (NASDAQ: CTEC) acquisition that Inverness announced Monday morning. In addition, we have gained greater comfort with the proposed Biosite (Nasdaq: BSTE) deal, and the ability of Inverness to derive significant cost savings from the combined organizations."
You May Also Be Interested In
- UPDATE: Nomura Securities Upgrades ASML Inc. (ASML) to Buy; Revenue Outlook Underestimated
- UBS Raises Estimates and Price Target on salesforce.com (CRM); Strong Quarter with Blowout Backlog
- Barclays Lowers PT and Estimates on Aruba Networks (ARUN); In-line Q3 and Weak Guidance Not Gonna Cut It
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
